Biogen Inc. Share Price and Company Fundamentals
Last traded: Yesterday at 8:00 PM
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Key Metrics
PE ratio
20.93
PB ratio
1.48
Dividend yield
-
Beta
0.16
Market cap
$26.97B
Enterprise value
$29.81B
Company profile
| Industry / Sector | Drug Manufacturers - General / Healthcare |
|---|---|
| Full time employees | 7500 |
| Website | https://www.biogen.com |
| Mailing address | 225 Binney Street Cambridge MA 02142 United States |
| Phone / Fax | 617 679 2000 / |
Dividends
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Biogen Inc. paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.BIIB dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Apr 2026, following are the company executives and directors listed on Biogen Inc..
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Christopher A. Viehbacher | President, CEO & Director | 64 | |
| Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer | 68 | |
| Dr. Priya Singhal M.D., M.P.H. | Executive VP & Head of Development | 56 | |
| Ms. Robin C. Kramer | Executive VP & CFO | 59 | |
| Mr. Sean Godbout | VP, Chief Accounting Officer & Global Corporate Controller | 51 | |
| Mr. Guy Hadari | Chief Information Officer | ||
| Mr. Tim Power M.B.A., Ph.D. | Head of Investor Relations | ||
| Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer | 57 | |
| Ms. Alisha A. Alaimo | President & Head of North America | ||
| Dr. Anabella Villalobos Ph.D. | Head of Biotherapeutics & Medicinal Sciences | 65 |
Profitability and management effectiveness
Profit margin
13.07%
Operating margin
19.64%
Return on assets
6.14%
Return on equity
7.39%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Biogen Inc. is 26.97B and its enterprise value is 29.81B. The enterprise value to revenue ratio of BIIB is 3.01. The enterprise value to EBITDA ratio of BIIB is 8.27.
The BIIB's stocks Beta value is 0.16 making it 84% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Biogen Inc. (NASDAQ:BIIB) Frequently Asked Questions
1. What is Biogen Inc.'s Stock Symbol?
Biogen Inc. trades on NASDAQ under the ticker symbol "BIIB".
2. What is Biogen Inc.'s stock price today?
One share of BIIB stock can currently be purchased for approximately $183.78.
3. How can I contact Biogen Inc.?
Biogen Inc.'s mailing address is 225 Binney Street Cambridge MA 02142 United States. The company can be reached via phone at 617 679 2000.
4. What is Biogen Inc.'s official website?
The official website of Biogen Inc. is https://www.biogen.com.